Opti Nose, Inc. OPTN
We take great care to ensure that the data presented and summarized in this overview for OptiNose, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OPTN
View all-
Mvm Partners, LLC Boston, MA14.6MShares$5.4 Million10.4% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT14.4MShares$5.31 Million0.57% of portfolio
-
Great Point Partners LLC Greenwich, CT12.9MShares$4.76 Million3.98% of portfolio
-
Stonepine Capital Management, LLC Bend, OR5.69MShares$2.1 Million2.41% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY5.6MShares$2.07 Million0.45% of portfolio
-
Black Rock Inc. New York, NY5.27MShares$1.95 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5MShares$1.85 Million0.0% of portfolio
-
Bleichroeder LP New York, NY4.05MShares$1.5 Million0.92% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.85MShares$1.43 Million0.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA3.08MShares$1.14 Million0.0% of portfolio
Latest Institutional Activity in OPTN
Top Purchases
Top Sells
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Insider Transactions at OPTN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 07
2024
|
Terry Kohler Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|
|
Sep 17
2024
|
Ramy A Mahmoud Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,881
-0.4%
|
$0
$0.87 P/Share
|
|
Sep 17
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
3,226
-0.59%
|
$0
$0.87 P/Share
|
|
Jul 17
2024
|
Ramy A Mahmoud Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
111,426
-8.45%
|
$111,426
$1.14 P/Share
|
|
Jul 17
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
49,408
-8.24%
|
$49,408
$1.14 P/Share
|
|
Jul 17
2024
|
Anthony J Krick Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,845
-4.64%
|
$6,845
$1.14 P/Share
|
|
Jun 18
2024
|
Anthony J Krick Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
624
-0.43%
|
$624
$1.19 P/Share
|
|
Jun 18
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
6,213
-0.51%
|
$6,213
$1.19 P/Share
|
|
Jun 18
2024
|
Ramy A Mahmoud Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,987
-1.42%
|
$18,987
$1.19 P/Share
|
|
Jun 15
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
3,817
+0.63%
|
-
|
|
Jun 15
2024
|
Ramy A Mahmoud Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,113
+0.46%
|
-
|
|
Mar 18
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
15,059
-2.44%
|
$15,059
$1.88 P/Share
|
|
Mar 18
2024
|
Anthony J Krick Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,345
-1.6%
|
$2,345
$1.88 P/Share
|
|
Mar 18
2024
|
Ramy A Mahmoud Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,198
-1.42%
|
$19,198
$1.88 P/Share
|
|
Mar 15
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
3,816
+0.61%
|
-
|
|
Mar 15
2024
|
Ramy A Mahmoud Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,114
+0.45%
|
-
|
|
Feb 28
2024
|
Ramy A Mahmoud Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
795,975
+37.19%
|
-
|
|
Feb 28
2024
|
Michael F Marino Iii Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
280,000
+31.34%
|
-
|
|
Feb 28
2024
|
Paul Spence Jr. Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
252,675
+50.0%
|
-
|
|
Feb 28
2024
|
Anthony J Krick Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+43.46%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.62M shares |
|---|
| Open market or private sale | 307K shares |
|---|